Suppr超能文献

原发性和复发性子宫平滑肌肉瘤手术治疗患者的预后因素及生存情况:单中心经验

Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.

作者信息

Bacalbasa Nicolae, Balescu Irina, Dima Simona, Brasoveanu Vladislav, Popescu Irinel

机构信息

Carol Davila U.M.F., Bucharest, Romania

Ponderas Hospital, Bucharest, Romania.

出版信息

Anticancer Res. 2015 Apr;35(4):2229-34.

Abstract

AIM

To (i) determine prognostic factors after initial surgery for uterine leiomyosarcomas (LMS) and their recurrence and (ii) assess the effectiveness of re-resections.

PATIENTS AND METHODS

All cases that underwent surgery for uterine leiomyosarcomas at the Fundeni Clinical Institute, Bucharest between 2002 and 2013 were reviewed. Twenty-six patients with primary uterine leiomyosarcomas were introduced in our study. Sixteen of them were re-addressed to the same hospital for recurrence.

RESULTS

At the moment of initial surgery the most important prognostic factors were age <60 years, International Federation of Gynecology and Obstetrics (FIGO) stage I, tumor dimension <15 cm and mitotic index <15/10 high-power fields (HPF). The five-year overall survival was 40%. Sixteen patients were re-operated for recurrence; the most important prognostic factors being a late recurrence (>12 months) and initial FIGO stage I. The five-year overall survival was 12.5%.

CONCLUSION

Uterine leiomyosarcoma is an aggressive malignancy with a high rate of recurrence. In selected cases surgery may be attempted for re-recurrence.

摘要

目的

(i) 确定子宫平滑肌肉瘤(LMS)初次手术后的预后因素及其复发情况,(ii) 评估再次手术切除的有效性。

患者与方法

回顾了2002年至2013年期间在布加勒斯特Fundeni临床研究所接受子宫平滑肌肉瘤手术的所有病例。本研究纳入了26例原发性子宫平滑肌肉瘤患者。其中16例因复发再次到同一家医院就诊。

结果

初次手术时,最重要的预后因素为年龄<60岁、国际妇产科联盟(FIGO)I期、肿瘤直径<15 cm以及有丝分裂指数<15/10个高倍视野(HPF)。五年总生存率为40%。16例患者因复发接受了再次手术;最重要的预后因素为复发较晚(>12个月)和初次FIGO I期。五年总生存率为12.5%。

结论

子宫平滑肌肉瘤是一种侵袭性恶性肿瘤,复发率高。在某些特定病例中,可尝试对再次复发进行手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验